Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes
Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users.
DexCom, Inc. (NASDAQDXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023.
DexCom, Inc. (NASDAQDXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM).
DexCom, Inc. (NASDAQDXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
DexCom, Inc. (NASDAQDXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Series D funding, with ŌURA now valued at more than $5 billion.
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.
